Accès ouvert
2026
article
OpenAlex
Judy E. Garber, D. Cameron, C. Campbell, G. Yothers et autres
BACKGROUND: The randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib (oral poly-(ADP-ribose) polymerase [PARP] inhibitor) to placebo in 1,836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 (gBRCApv) germline variants and high-risk human epidermal growth factor receptor 2 (HER2)-negative …
us, gb, sg, be, pl, es, fr, tw, se, de, it, kr, jp, ch, is, ar, au, at, ca, nl, cn, ie
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
K.H. Allison, Shannon McKernin, Lisa A. Carey, J. Perlmutter et autres
Purpose.-To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. Methods.-A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by …
us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
M.M. Regan, W.F. Symmans, M. Dowsett, S.R. Lakhani et autres
PURPOSE To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed …
us
(code pays fourni par la source)